Core Viewpoint - Integer Holdings Corporation has faced significant challenges, leading to a class action lawsuit due to misleading statements regarding its business performance and sales projections [4]. Financial Performance - On October 23, 2025, Integer reduced its full-year 2025 sales guidance to a range of $1.840 billion to $1.854 billion, which was below prior expectations [2]. - The company anticipated net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026 [2]. - Sales of three new products, including two electrophysiology devices, were expected to decline in 2026, with slower market adoption than forecasted [2]. Stock Market Reaction - Following the announcement of reduced sales guidance, Integer's stock price fell by $35.22 per share, or 32.3%, closing at $73.89 per share on October 23, 2025 [3]. Lawsuit Details - The class action lawsuit alleges that Integer made materially false and misleading statements and failed to disclose adverse facts about its business and operations [4]. - Specific allegations include overstating its competitive position in the electrophysiology manufacturing market and mischaracterizing its EP devices as long-term growth drivers [4]. Legal Action - Investors who purchased Integer common stock during the class period (July 25, 2024, to October 22, 2025) have until February 9, 2026, to file a lead plaintiff motion in the class action [1][5].

Core Viewpoint - A securities fraud class action lawsuit has been filed against Integer Holdings Corporation, alleging misrepresentations regarding its market position and overstated demand for its electrophysiology devices [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired Integer common stock between July 25, 2024, and October 22, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Integer and certain senior officers [3]. Group 2: Legal Actions and Deadlines - Investors wishing to serve as lead plaintiff must file necessary documents by February 9, 2026 [5]. - Serving as a lead plaintiff allows representation of other class members in directing the litigation, but it is not required to share in any potential recovery [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts regarding its business performance during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit claims that the company mischaracterized its growth drivers, leading to a significant decline in stock price following the revelation of these issues [3]. Group 3: Impact of Disclosures - On October 23, 2025, Integer reduced its sales guidance and disclosed an expected sales decline, resulting in a stock price drop of $35.22 per share, which is over 32% in a single trading day [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Performance and Guidance - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026 [6]. - The announcement led to a drastic decline in Integer's stock price, dropping $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - Integer Holdings Corporation will host a conference call to discuss its financial results and business highlights for Q4 and the full year of 2025 on February 19, 2026 [1] Group 1: Conference Call Details - The conference call is scheduled for February 19, 2026, at 8 a.m. CT / 9 a.m. ET [1] - An audio replay of the conference call will be available for seven days, accessible by dialing (800) 770-2030 or (609) 800-9909 with Conference ID 3120125 [2] - The call will also be available live and via archived replay on the Investor Relations section of the Integer website [2] Group 2: Company Overview - Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations (CDMO) globally, serving markets such as cardiac rhythm management and neuromodulation [4] - The company aims to enhance patient lives by providing innovative, high-quality products and solutions [4] - Integer's brands include Greatbatch Medical and Lake Region Medical [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Integer Holdings Corporation during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Integer common stock between July 25, 2024, and October 22, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Case Allegations - The lawsuit alleges that Integer Holdings Corporation made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market and mischaracterized its EP devices as growth drivers [5]. - It is claimed that Integer experienced a deterioration in sales for two of its EP devices, contradicting its claims of strong customer demand [5].

Core Viewpoint - Integer Holdings Corporation is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market [3]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for the cardio & vascular segment [3]. - As a result of these issues, the defendants' positive statements about the company's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025 [3]. - Shareholders who purchased shares during this period are encouraged to register for the class action, with a deadline of February 9, 2026, to seek lead plaintiff status [4]. - There is no cost or obligation for shareholders to participate in the case [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Integer common stock between July 25, 2024, and October 22, 2025, inclusive [2]. - Investors have until February 9, 2026, to apply to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that the company materially overstated its competitive position in the EP manufacturing market [3]. - It claims that despite the company's assertions of strong customer demand visibility, there was a sustained deterioration in sales for two of its EP devices [3]. - The company mischaracterized its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about its business and prospects [3]. Group 3: Next Steps for Investors - Investors who purchased Integer shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business performance and sales guidance [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities between July 25, 2024, and October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against Integer - The company is accused of overstating its competitive position and failing to disclose declining sales of electrophysiology devices [3]. - Integer mischaracterized its growth drivers, leading to misleading representations about its business [3]. Group 3: Impact on Stock Price - Following a sales guidance reduction on October 23, 2025, Integer's stock price fell by $35.22 per share, a decrease of over 32% in one trading day [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].